Jerusalem, 31 July, 2025 (TPS-IL) — Israeli-American biotech company OncoHost has been named the Top Precision Oncology Solution for 2025 by Life Sciences Review. The award recognizes the company’s AI-powered PROphet platform, which personalizes cancer treatment by analyzing thousands of plasma proteins to predict therapy response and toxicities.
Headquartered in Binyamina and Cary, NC, OncoHost’s technology is currently used in treating advanced non-small cell lung cancer, with new applications in development for melanoma, renal cell carcinoma, and immune-related side effects.
“This is a powerful endorsement of our vision,” said CEO Dr. Ofer Sharon. “We’re shifting the lens from tumor biology to the full biological context of the patient.”